ReviewBiomedicines2026
Induced Pluripotent Stem Cells in Corneal Regeneration: Biological Progress, Translational Barriers and Clinical Outlook.
Review in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Corneal blindness remains a major cause of visual impairment worldwide and may result from trauma, infectious keratitis, degenerative disorders, endothelial dysfunction, and limbal stem cell deficiency (LSCD). Although corneal transplantation remains the standard treatment for advanced disease, its effectiveness is limited by donor tissue shortage, immune-mediated rejection, postoperative complications, and progressive graft failure. These limitations have accelerated interest in regenerative approaches aimed at restoring native corneal structure and function. Induced pluripotent stem cells (iPSCs) have emerged as a promising platform for corneal regeneration because of their pluripotency, self-renewal capacity, and potential for autologous or immune-compatible therapy. Recent advances in differentiation protocols have enabled the generation of corneal epithelial-like cells, stromal keratocyte-like cells, and corneal endothelial-like cells from iPSCs. Preclinical studies have demonstrated encouraging improvements in corneal transparency, epithelial restoration, fibrosis reduction, and endothelial function, while early clinical investigations, particularly in LSCD, have reported favorable short-term safety and functional outcomes. However, major translational barriers remain, including tumorigenicity, immunogenicity, genomic instability, manufacturing complexity, scalability, and long-term safety concerns. Stromal regeneration also remains comparatively underdeveloped relative to epithelial and endothelial applications. This review summarizes current differentiation strategies, biological mechanisms, preclinical and early clinical evidence, and the principal translational challenges associated with iPSC-based corneal regeneration. Overall, iPSC-derived corneal therapies demonstrate considerable regenerative potential, although further standardization, long-term safety evaluation, and multicenter clinical validation remain necessary before widespread clinical adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.